Literature DB >> 16522262

Tension-type headache.

Ninan T Mathew1.   

Abstract

Tension-type headache, the most common type of primary headache disorder, is reclassified in the second International Headache Society classification with clear diagnostic criteria. Chronic tension-type headache (CTTH) differs from episodic form in frequency, lack of response to most treatment strategies, more medication overuse, and more loss of quality of life. New concepts in the pathophysiology of CTTH emphasize the possible role of central nociceptive pathway sensitization in addition to peripheral myogenic factors. Mechanisms of central sensitization, even though poorly understood, may involve nitric oxide system and N-methyl-D-aspartate receptors. Future treatment modalities are likely to be based on such mechanisms. Using MRI and voxel-based morphometry, structural abnormalities have been found in patients with CTTH for the first time. Pain processing areas such as dorsal rostral and ventral pons, anterior cingulate cortex, anterior and posterior insular cortex, right posterior temporal lobe, orbitofrontal cortex, para hippocampus bilaterally, and the right cerebellum were found to have decreased gray matter in patients with CTTH compared with control subjects and patients with medication overuse headache. Amitriptyline remains the most effective preventive treatment so far. The role of botulinum toxin is not fully defined.

Entities:  

Mesh:

Year:  2006        PMID: 16522262     DOI: 10.1007/s11910-996-0031-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  36 in total

1.  Decreased pain detection and tolerance thresholds in chronic tension-type headache.

Authors:  L Bendtsen; R Jensen; J Olesen
Journal:  Arch Neurol       Date:  1996-04

Review 2.  Neuronal plasticity: increasing the gain in pain.

Authors:  C J Woolf; M W Salter
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

3.  Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache.

Authors:  L Bendtsen; R Jensen
Journal:  Cephalalgia       Date:  2000-07       Impact factor: 6.292

4.  Nitric oxide-induced headache in patients with chronic tension-type headache.

Authors:  M Ashina; L Bendtsen; R Jensen; J Olesen
Journal:  Brain       Date:  2000-09       Impact factor: 13.501

Review 5.  The role of imaging in the pathophysiology and diagnosis of headache.

Authors:  Arne May
Journal:  Curr Opin Neurol       Date:  2005-06       Impact factor: 5.710

Review 6.  Central sensitization in tension-type headache--possible pathophysiological mechanisms.

Authors:  L Bendtsen
Journal:  Cephalalgia       Date:  2000-06       Impact factor: 6.292

7.  The International Headache Society (IHS) headache classification as applied to a headache clinic population.

Authors:  L C Sanin; N T Mathew; L R Bellmeyer; S Ali
Journal:  Cephalalgia       Date:  1994-12       Impact factor: 6.292

8.  Cephalic and extracephalic pressure pain thresholds in chronic tension-type headache.

Authors:  J Schoenen; D Bottin; F Hardy; P Gerard
Journal:  Pain       Date:  1991-11       Impact factor: 6.961

9.  Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial.

Authors:  M Ashina; L H Lassen; L Bendtsen; R Jensen; J Olesen
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

10.  Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats.

Authors:  J C Eisenach; G F Gebhart
Journal:  Anesthesiology       Date:  1995-11       Impact factor: 7.892

View more
  2 in total

Review 1.  The role of muscles in tension-type headache.

Authors:  Lars Bendtsen; César Fernández-de-la-Peñas
Journal:  Curr Pain Headache Rep       Date:  2011-12

2.  Botulinum toxin: could it be an effective treatment for chronic tension-type headache?

Authors:  Sherif M Hamdy; Hatem Samir; M El-Sayed; Nermin Adel; Rasha Hasan
Journal:  J Headache Pain       Date:  2008-11-22       Impact factor: 7.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.